Apr. 17, 2026
Boundless Bio Presents Preclinical Breast Cancer Data from Kinesin Degrader Program
Findings support ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader.
Apr. 17, 2026
MiNK Therapeutics Reports Promising Phase II Data on Immune Reprogramming and Survival in PD-1 Refractory Gastroesophageal Cancer
Combination therapy with agenT-797, botensilimab, and balstilimab shows high disease control rate and long-term survival in subset of patients
Apr. 17, 2026
Xilio Therapeutics Unveils Promising Preclinical Data for Masked T Cell Engager XTX601
New findings at AACR Annual Meeting highlight potential for wide therapeutic index and favorable tolerability profile
Apr. 17, 2026
Pyxis Oncology Presents Promising Preclinical Data on MICVO for HNSCC
Combination with anti-PD-1 shows synergistic anti-tumor activity in immunotherapy-refractory model
Apr. 17, 2026
ORIC Pharmaceuticals Presents Prostate Cancer Potential of Rinzimetostat at AACR
Preclinical data highlights rinzimetostat's ability to overcome resistance and improve response to androgen receptor therapies.
Apr. 17, 2026
Accent Therapeutics Presents Promising Data on Novel KIF18A Inhibitor ATX-295 at AACR
Preclinical results demonstrate robust anti-cancer activity of ATX-295 in chromosomally unstable tumor models
Apr. 17, 2026
Moderna to Present Phase 1/2 Data on Cancer Therapy mRNA-4359 at AACR
The investigational therapy showed promising results in combination with pembrolizumab for locally advanced or metastatic melanoma.
Apr. 17, 2026
GigaGen presents positive phase 1 data on non-blocking anti-CTLA-4 drug candidate GIGA-564
GIGA-564 demonstrated a favorable safety profile while exhibiting early signals of anti-tumor activity in solid tumors
Apr. 17, 2026
Sleep Loss Linked to Gut Bacteria Changes, Worsening Colon Cancer
UF Health researchers find sleep deprivation alters microbiome, weakens immune system and chemotherapy response
Apr. 16, 2026
Calidi Biotherapeutics to Showcase Advancing Clinical Pipelines at RedChip Virtual Investor Conference
The biotech company will present its novel RedTail virotherapy platform and lead candidate CLD-401 at the April 16 event.
Apr. 16, 2026
Mount Sinai and SOPHiA GENETICS Partner on Precision Cancer Care
Collaboration aims to advance AI-driven personalized cancer treatment at leading academic health system.
Apr. 15, 2026
Debiopharm Unveils New Cancer Research at AACR 2026
Preliminary data from MYTHIC study, dual payload ADCs, and AI-driven biomarkers to be presented
Apr. 15, 2026
EpimAb Biotherapeutics to Present Novel Prodrug T-Cell Engager Platform at AACR
The biotechnology company will showcase its innovative cancer treatment technology at the upcoming cancer research conference.
Apr. 15, 2026
OBI Pharma Showcases Advancements in Glycan-Based ADCs at AACR 2026
Ten poster presentations highlight the transformative potential of the company's GlycOBI® platform for next-generation antibody-drug conjugates.
Apr. 14, 2026
Mestag Therapeutics to Present Targeted Cancer Therapy at AACR
Biotech company selected for late-breaking poster on FAP-targeted LTBR agonist MST-0312 at major oncology conference.
Apr. 14, 2026
Roswell Park Teams Bring Latest Real-World Data, New Strategies to Treat Aggressive Cancers to AACR 2026
Researchers to present groundbreaking work at major cancer research conference
